Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for February 6, 2025. The earnings press release will be issued at 1:00 PM PT, followed by a conference call at 1:30 PM PT. The company, a leading neuroscience-focused biopharmaceutical firm, focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.

The company's portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Additionally, they maintain multiple compounds in mid- to late-phase clinical development across their core therapeutic areas.

Positive

• Diverse portfolio of FDA-approved treatments across multiple conditions
• Multiple compounds in mid to late-phase clinical development

Negative

• None.

Conference Call and Webcast Scheduled for Thursday, February 6

SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025.

The schedule for the press release and conference call / webcast is as follows:

• Q4 & Year-End 2024 Press Release: February 6, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
• Q4 & Year-End 2024 Conference Call: February 6, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-225-9448
• International Dial-In Number: 203-518-9708
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2024-financial-results-302364771.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will NBIX release its Q4 and year-end 2024 financial results?

Neurocrine Biosciences will release its Q4 and year-end 2024 financial results on February 6, 2025, at 1:00 PM Pacific Time (4:00 PM Eastern Time).

How can investors access NBIX's Q4 2024 earnings call?

Investors can access the call via phone (800-225-9448 domestic, 203-518-9708 international) or through the webcast on Neurocrine's website under the Investors section.

What therapeutic areas does NBIX focus on?

NBIX focuses on neurological, neuroendocrine, and neuropsychiatric disorders, developing treatments for conditions like tardive dyskinesia, Huntington's disease chorea, and congenital adrenal hyperplasia.

Which FDA-approved treatments are in NBIX's current portfolio?

NBIX's portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids (the latter two in collaboration with AbbVie).